All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-11-09T15:10:10.000Z

Quizartinib granted approval by the EC for patients with newly diagnosed FLT3-ITD-mutated AML

Nov 9, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new development in the treatment of AML.

On November 9, 2023, quizartinib, an oral selective type II FLT3 inhibitor, was approved by the European Commission (EC) in combination with standard cytarabine and anthracycline induction, standard cytarabine consolidation chemotherapy, and as a maintenance monotherapy for the treatment of adult patients with newly diagnosed FLT3-ITD-mutated acute myeloid leukemia.1

This approval is based on a recent positive opinion by the European Medicines Agency’s Committee of Medicinal Products for Human Use, previously covered by the AML Hub, and results from the QuANTUM-First trial (NCT02668653).1 Quizartinib has also been approved by the U.S. Food and Drug  Administration and in Japan for the same indication.

  1. Daiichi-Sankyo. VANFLYTA approved in the EU as the first FLT3 inhibitor specifically for patients with newly diagnosed FLT3-ITD positive AML. https://www.daiichisankyo.com/files/news/pressrelease/pdf/202311/20231109_E.pdf. Published Nov 9, 2023. Accessed Nov 9, 2023.

Related articles

Newsletter

Subscribe to get the best content related to AML delivered to your inbox